Media coverage about Aduro Biotech (NASDAQ:ADRO) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aduro Biotech earned a news impact score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.319725341823 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several equities research analysts have recently commented on the company. BidaskClub cut Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Zacks Investment Research cut Aduro Biotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 2nd. Canaccord Genuity reissued a “buy” rating and issued a $30.00 target price on shares of Aduro Biotech in a research note on Wednesday, May 3rd. HC Wainwright assumed coverage on Aduro Biotech in a research note on Monday, May 1st. They issued a “buy” rating and a $18.00 target price for the company. Finally, Cowen and Company assumed coverage on Aduro Biotech in a research note on Tuesday, July 18th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $19.00.
Aduro Biotech (NASDAQ:ADRO) traded down 3.15% on Friday, hitting $10.75. The stock had a trading volume of 301,795 shares. The company’s market capitalization is $802.08 million. Aduro Biotech has a 12-month low of $8.75 and a 12-month high of $15.83. The company has a 50 day moving average of $12.44 and a 200 day moving average of $10.98.
Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $5.90 million during the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The business’s revenue for the quarter was down 84.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 earnings per share. On average, equities analysts expect that Aduro Biotech will post ($1.37) earnings per share for the current year.
In other Aduro Biotech news, insider Thomas W. Dubensky sold 144,301 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $10.03, for a total transaction of $1,447,339.03. Following the completion of the sale, the insider now directly owns 117,871 shares in the company, valued at approximately $1,182,246.13. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jennifer Lew sold 12,000 shares of the stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $11.19, for a total value of $134,280.00. Following the sale, the insider now owns 54,595 shares of the company’s stock, valued at $610,918.05. The disclosure for this sale can be found here. Insiders sold 561,624 shares of company stock valued at $6,232,065 over the last 90 days. 6.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Aduro Biotech (ADRO) Stock Price” was reported by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://rinconhillneighbors.org/2017/08/19/aduro-biotech-adro-earning-somewhat-favorable-news-coverage-study-finds-updated-updated.html.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with our FREE daily email newsletter.